Amica Retiree Medical Trust Invests $295,000 in Zoetis Inc. $ZTS

Amica Retiree Medical Trust bought a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,891 shares of the company’s stock, valued at approximately $295,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after buying an additional 189,287 shares during the period. Polen Capital Management LLC grew its position in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. Northern Trust Corp increased its stake in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Zoetis by 4.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,252,697 shares of the company’s stock worth $700,207,000 after acquiring an additional 174,119 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.5%

NYSE:ZTS opened at $120.20 on Friday. The business has a fifty day moving average price of $144.21 and a 200-day moving average price of $152.61. The firm has a market capitalization of $53.27 billion, a price-to-earnings ratio of 20.69, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a one year low of $117.26 and a one year high of $181.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the firm earned $1.58 earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is 33.67%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus set a $140.00 price objective on shares of Zoetis in a report on Tuesday. JPMorgan Chase & Co. dropped their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday. UBS Group reduced their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $191.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.